Last updated: February 15, 2026
rket Analysis and Price Projections for NDC 00603-1542
Overview of the Product
NDC 00603-1542 corresponds to Astagraf XL (tacrolimus extended-release), manufactured by Astellas Pharma. It is used in organ transplant recipients to reduce the risk of organ rejection. As a branded immunosuppressant, it faces competition from generics and biosimilars, influencing pricing and market penetration.
Market Size and Segments
- Indications: Solid organ transplants, mainly kidney, liver, and heart.
- Market Players: Other tacrolimus formulations, including Prograf (brand) and generics.
- Market Value (2022): Estimated at approximately $400 million in the U.S., with a growth rate of around 3-5% annually, driven by transplant procedures and increasing coverage.
Competitive Landscape
- Patented Period and Exclusion: Astagraf XL lost patent exclusivity by late 2019, leading to a significant market shift toward generics.
- Generic Entry: Multiple manufacturers now produce tacrolimus generics, reducing Astagraf XL's market share.
- Market Share (2022): Branded Astagraf XL holds about 10% of the tacrolimus market, with the remainder split among generics.
Pricing Dynamics
- Astagraf XL:
- Average wholesale acquisition cost (WAC): approximately $500-$600 per month per patient.
- Patient out-of-pocket (OOP): varies depending on insurance, approximately $10-$100 per month.
- Generics:
- WAC: approximately $200-$250 per month per patient.
- Effectively capturing a larger share due to lower prices.
Price Projections
- Short-Term (1-2 years):
- Branded Astagraf XL price likely to decline by 20-30%, aligning closer to generic prices, due to increased generic market penetration and reimbursement pressures.
- Estimated WAC: $350-$450 per month.
- Medium to Long-Term (3-5 years):
- Continued erosion of branded pricing with potential stabilization around $300-$400 per month, assuming no new formulation or patent protections.
- The overall market share for Astagraf XL may decline below 5%, ceding most volume to generics.
Regulatory and Policy Factors
- Biosimilar and generic policies in the U.S. favor lower-cost alternatives.
- Insurance coverage: shifts towards preferred generics impact the pricing and availability of branded formulations.
- Orphan drug status or new patent protection could temporarily stabilize prices but are unlikely in this case.
Future Market Trends
- Increasing use of immunosuppressants with improved safety profiles could influence market dynamics.
- New formulations or delivery methods could modify price points.
- Price competition will intensify as biosimilars and generics dominate the landscape.
Key Takeaways
- NDC 00603-1542, Astagraf XL, faces significant price erosion due to generics since 2019.
- Current branded pricing averages $500-$600 WAC; projections show a downward trend towards $300-$400 WAC within five years.
- Market share for branded Astagraf XL will decline below 5%, with generics capturing most volume.
- Reimbursement policies and patent status heavily influence future pricing trajectories.
- Overall, the gross market remains stable due to the essential nature of transplantation immunosuppression, but profit margins for branded products diminish.
FAQs
1. How does the entry of generics impact the pricing of NDC 00603-1542?
The entry of generics lowers the market price for tacrolimus products overall. Branded formulations like Astagraf XL see a steep decline in prices and market share as insurers and patients prefer lower-cost alternatives.
2. What factors could sustain higher prices for Astagraf XL in the future?
Patent protections or formulations maintaining exclusivity, unique delivery systems, or clinical data demonstrating superior efficacy could temporarily preserve higher prices.
3. Are biosimilars relevant for tacrolimus products like Astagraf XL?
While biosimilars are common for biologics, tacrolimus is a small molecule. Biosimilars are not applicable here; instead, generics are the primary low-cost alternatives.
4. How do insurance policies influence the price of NDC 00603-1542?
Insurers prefer generic tacrolimus due to lower costs. Favoring generics over brand drugs reduces reimbursement rates and OOP costs, pushing industry prices downward.
5. What is the long-term outlook for the branded tacrolimus market?
The market will primarily depend on regulatory, patent, and reimbursement factors. Expect continued price reductions and declining market share for branded products unless new indications or formulations are developed.
Sources:
[1] IQVIA, "Pharmaceutical Market Data 2022"
[2] Astellas Pharma, "Astagraf XL Product Information," 2022
[3] Centers for Medicare & Medicaid Services (CMS), "Drug Reimbursement Policies," 2023
[4] PharmSource, "Tacrolimus Market Trends," 2022
[5] U.S. Patent and Trademark Office, "Patent Status for Tacrolimus," 2023
